Consensus Report
Metformin
Moderate Consensus
out of 5
Based on 44 videos (68 hours analyzed) across 5 experts · Updated 2026-03-23
Expert Positions
The Verdict
Metformin is the most debated longevity drug among the 5 experts. Attia has extensively covered it across 27+ videos but shifted from cautious optimism to skepticism, concluding it may be a mitochondrial toxin for healthy individuals. Huberman explicitly avoids it for longevity. Hyman acknowledges it as the safest diabetes drug but favors lifestyle interventions over pharmacological approaches. Patrick has minimal coverage. Johnson includes metformin in his Blueprint protocol but is discussed only via Hyman's channel.
Where They Disagree
Attia fundamentally shifted from cautious optimism to active skepticism about metformin for longevity in healthy individuals, while Barzilai (a frequent guest on Attia's show) continues to champion it through the TAME trial as a geroprotective agent.
Huberman avoids metformin entirely for longevity, citing insufficient human data, while Johnson actively takes it as part of his Blueprint protocol based on his data-driven approach.
+ 3 more disagreements in the full report
About This Analysis
This consensus report on Metformin is based on 44 videos (68 hours analyzed) from five longevity experts: Andrew Huberman, Peter Attia, Rhonda Patrick, Bryan Johnson, and Mark Hyman. Each expert's position was independently analyzed from their published video content, including lectures, podcast episodes, and Q&A sessions with 1,000+ guest scientists.
The full report includes 9 key findings, dosage and protocol details, expert deep dives with direct video citations and timestamps, risk considerations, and related supplement synergies.
Unlock the Full Report
Get dosages, timing protocols, expert deep dives with video citations, and risks for Metformin.
Every recommendation traces back to a specific expert, video, and timestamp.
$9/month or $79/year · Cancel anytime